Richard Friedman to Risk Assessment
This is a "connection" page, showing publications Richard Friedman has written about Risk Assessment.
Connection Strength
0.182
-
Dabigatran versus enoxaparin for prevention of venous thromboembolism after hip or knee arthroplasty: a pooled analysis of three trials. Thromb Res. 2010 Sep; 126(3):175-82.
Score: 0.056
-
Dabigatran etexilate: pivotal trials for venous thromboembolism prophylaxis after hip or knee arthroplasty. Clin Appl Thromb Hemost. 2009 Sep-Oct; 15 Suppl 1:25S-31S.
Score: 0.053
-
Optimal duration of prophylaxis for venous thromboembolism following total hip arthroplasty and total knee arthroplasty. J Am Acad Orthop Surg. 2007 Mar; 15(3):148-55.
Score: 0.045
-
Benefit-risk assessment of rivaroxaban versus enoxaparin for the prevention of venous thromboembolism after total hip or knee arthroplasty. Vasc Health Risk Manag. 2014; 10:157-67.
Score: 0.018
-
Treatment of venous thromboembolism: adherence to guidelines and impact of physician knowledge, attitudes, and beliefs. J Vasc Surg. 2005 Oct; 42(4):726-33.
Score: 0.010